The Relationship Between Antiretroviral Therapy Initiation and the Development of Immune Reconstitution Inflammatory Syndrome: A Review of Foundational Concepts

Abstract

Introduction: The introduction of effective antiretroviral therapy (ART) transformed the prognosis for patients with HIV, allowing for robust restoration of the immune system. However, this immune recovery can precipitate a paradoxical clinical worsening known as Immune Reconstitution Inflammatory Syndrome (IRIS), a significant complication of treatment initiation.

Literature Review: A review of the pivotal literature defines IRIS as an aberrant and exaggerated inflammatory response directed against underlying opportunistic pathogens, which is "unmasked" following the start of ART. The pathogenesis is attributed to the rapid quantitative and qualitative recovery of the immune system, particularly pathogen-specific CD4+ T-cells, leading to a surge of pro-inflammatory cytokines. Foundational clinical studies identified the primary risk factors for developing IRIS, including a very low baseline CD4+ T-cell count and the presence of a high burden of an opportunistic infection at the time ART is commenced. The clinical dilemma of when to initiate ART in patients with active co-infections, most notably tuberculosis, became a central challenge, requiring a careful balance between the risk of IRIS and the risk of ongoing immunodeficiency.

Conclusion: The body of evidence established IRIS as a common and clinically important consequence of successful ART. This research was essential for defining the syndrome, understanding its immunopathology, and developing clinical strategies to anticipate and manage this paradoxical complication in patients with advanced HIV disease.